Compare Elastic NV (ESTC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Vertex Pharmaceuticals Incorporated — how do they compare? Elastic NV trades at $95.26 (market cap $9.77B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.1× Elastic NV's market cap, and Elastic NV is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ESTC | VRTX | |
|---|---|---|
Market Cap | $9.77B | $128.16B |
Volume | 945,514 | 806,603 |
Sector | Technology | Health |
52-Week High | $99.91 | $557.96 |
52-Week Low | $43.30 | $407.37 |
Typical Hold Time | 10 Days | 120 Days |
Enterprise Value | $8.91B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $93.1, down 1.59% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust revenue growth, improving profitability into 2026, and positive sentiment from analysts, with 22 buy ratings and no sells. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in its observability and search platforms.
The stock presents a growth opportunity driven by product innovation and expanding profit margins, but risks include high valuation multiples and competitive pressures in the enterprise software sector. Analyst consensus targets $79.50, below the current price, suggesting cautious optimism amid execution risks and market volatility.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
